Jiayu Zhu1, Hua Wang2,3,4, Cheng-Cheng Liu5,6, Yue Lu7,5,6, Hailin Tang8,9,10. 1. Department of Obstetrics and Gynecology, Nanfang Hospital of Southern Medical University, Guangzhou, 510515, Guangdong, People's Republic of China. 2. Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China. wanghua@sysucc.org.cn. 3. State Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China. wanghua@sysucc.org.cn. 4. Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China. wanghua@sysucc.org.cn. 5. State Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China. 6. Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China. 7. Department of Hematological Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China. 8. Department of Breast Oncology, SunYat-Sen University Cancer Center, Guangzhou, 510060, Guangdong, People's Republic of China. tanghl@sysucc.org.cn. 9. State Key Laboratory of Oncology in South China, Guangzhou, 510060, Guangdong, People's Republic of China. tanghl@sysucc.org.cn. 10. Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, Guangdong, People's Republic of China. tanghl@sysucc.org.cn.
Abstract
PURPOSE: The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score systems composed of C-reactive protein and albumin, has been reported to be predictive of survival in several types of malignancies. The prognostic significance of GPS in epithelial ovarian cancer (EOC) remains unclear. We conducted this study to assess the prognostic value of GPS in a cohort of patients with advanced EOC receiving neoadjuvant chemotherapy (NAC) followed by debulking surgery. METHODS: Six hundred and seventy-two patients newly diagnosed with advanced EOC were retrospectively analyzed. RESULTS: High GPS was significantly related to Eastern Cooperative Group performance status, histological type, histological grade and the size of residual tumor after the debulking surgery. In addition, patients with higher GPS at diagnosis achieved lower complete remission rates after NAC (P < 0.05) and had shorter progression-free survival (PFS; P < 0.001) and overall survival (OS; P < 0.001). Multivariate analysis showed high GPS was independent adverse predictors of PFS and OS. CONCLUSIONS: Our data demonstrated that GPS at diagnosis is a powerful independent prognostic factor for advanced epithelial ovarian cancer. However, further studies are needed to prospectively validate this prognostic model and investigate the mechanisms underlying the correlation between high GPS and poor prognosis in advanced epithelial ovarian cancer.
PURPOSE: The Glasgow Prognostic Score (GPS), an inflammation-based prognostic score systems composed of C-reactive protein and albumin, has been reported to be predictive of survival in several types of malignancies. The prognostic significance of GPS in epithelial ovarian cancer (EOC) remains unclear. We conducted this study to assess the prognostic value of GPS in a cohort of patients with advanced EOC receiving neoadjuvant chemotherapy (NAC) followed by debulking surgery. METHODS: Six hundred and seventy-two patients newly diagnosed with advanced EOC were retrospectively analyzed. RESULTS: High GPS was significantly related to Eastern Cooperative Group performance status, histological type, histological grade and the size of residual tumor after the debulking surgery. In addition, patients with higher GPS at diagnosis achieved lower complete remission rates after NAC (P < 0.05) and had shorter progression-free survival (PFS; P < 0.001) and overall survival (OS; P < 0.001). Multivariate analysis showed high GPS was independent adverse predictors of PFS and OS. CONCLUSIONS: Our data demonstrated that GPS at diagnosis is a powerful independent prognostic factor for advanced epithelial ovarian cancer. However, further studies are needed to prospectively validate this prognostic model and investigate the mechanisms underlying the correlation between high GPS and poor prognosis in advanced epithelial ovarian cancer.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Jing Yang; Michele Wezeman; Xiang Zhang; Pei Lin; Michael Wang; Jianfei Qian; Bo Wan; Larry W Kwak; Long Yu; Qing Yi Journal: Cancer Cell Date: 2007-09 Impact factor: 31.743
Authors: Andrew Bryant; Shaun Hiu; Patience T Kunonga; Ketankumar Gajjar; Dawn Craig; Luke Vale; Brett A Winter-Roach; Ahmed Elattar; Raj Naik Journal: Cochrane Database Syst Rev Date: 2022-09-26
Authors: Dmitry M Ponomarenko; Irina D Klimova; Yulia A Chapygina; Viktoria V Dvornichenko; Natalia V Zhukova; Rashida V Orlova; Georgy M Manikhas; Alexandr V Zyryanov; Lilya A Burkhanova; Irina I Badrtdinova; Basile N Oshchepkov; Elena V Filippova; Sergei V Orlov; Sergei I Kolesnikov; Albert A Sufianov; Svetlana R Baum; Olga Y Zaitzeva; Andrey B Komissarov; Mikhail P Grudinin; Oleg I Kiselev; Anatoly F Tsyb; Franco Venanzi; Vita Shcherbinina; Andrey Chursov; Vladimir L Gabai; Alexander M Shneider Journal: Oncotarget Date: 2017-03-25